Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

QIAGEN Teams with China’s Lepu Medical

Published: Friday, September 14, 2012
Last Updated: Friday, September 14, 2012
Bookmark and Share
Collaboration to provide rapid diagnosis of heart attacks using point of need testing.

QIAGEN N.V. announced an agreement with Lepu Medical Technology (Beijing) Co., Ltd., a leading medical device company in China, to provide QIAGEN’s ESEQuant Lateral Flow System for use in emergency rooms with Lepu’s tests for cardiac markers that diagnose acute myocardial infarction (heart attack). The agreement expands QIAGEN’s presence in China and adds a new point of need diagnostics application.

China’s State Food and Drug Administration (SFDA) has approved the ESEQuant Lateral Flow detection system with Lepu Medical’s five cardiac marker tests. Lepu will market the system in China under the name LEPU Quant-Gold. Globally, this is the first regulatory approval in human healthcare for QIAGEN’s pioneering ESEQuant platform which was acquired in 2010.

“We are very pleased to begin this relationship with the Lepu Group and meet a pressing need for heart patients by combining ESEQuant’s quick turnaround time with the reliability of Lepu’s tests for cardiac biomarkers,” said Dr. Frank Krieg-Schneider, Head of Global Strategic Alliances & OEM at QIAGEN. “This agreement advances two strategic initiatives: First, our geographic presence is further broadened by the addition of important point of need assays in China. China today represents QIAGEN’s third-largest country in sales. Secondly, we are driving platform success by launching ESEQuant as an SFDA-approved device in a lifesaving medical application, a milestone for our emerging Point of Need portfolio.”

QIAGEN's Point of Need portfolio is rapidly expanding. The growth is based on the benefits of the revolutionary ESE platform portfolio as well as on the value of the pipeline and portfolio of molecular and other assays for these platforms. Earlier in 2012 QIAGEN acquired the AmniSure immunoassay for rupture of amniotic membranes in pregnant women, a self-contained test used in doctor’s offices and maternity units, and joined a global initiative with the Bill and Melinda Gates Foundation to create much-needed platforms for point of care diagnosis in the developing world. “Our vision for point of need is to bring the speed and reliability of advanced diagnostics into emergency rooms, physician offices and other places where care is given without immediate access to laboratories”, Dr. Krieg-Schneider added.

The agreement with Lepu Medical begins with shipment of 750 ESEQuant systems for China and is expected to grow. The need in emergency rooms is for quick response with appropriate treatments, since patients suffering heart attacks face the greatest risk of death in the first hour. Currently, ambulance personnel take samples to test for cardiac markers, and upon arrival at the hospital these are sent to a laboratory – a delay of an hour or more. QIAGEN’s ESEQuant platform will run Lepu’s tests to measure key cardiac markers immediately after the ambulance arrives at the emergency room, allowing accurate diagnosis within minutes at the point of care – a lifesaving improvement. China has more than 14,000 public hospitals and an additional 5,700 private hospitals, according to 2009 public data.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN,Biotype Diagnostics Form Partnership
New “Biotype Innovation” to develop workflows for personalized health-care and other applications based on QIAGEN’s ModaPlex platform.
Monday, June 29, 2015
Hitachi High-Technologies, QIAGEN Collaborate
Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Thursday, June 18, 2015
QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, Astellas CDx Partnership
Collaboration provides options for collaboration across therapeutic areas, sample types and testing technologies.
Thursday, October 30, 2014
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Receives FDA Clearance for QIAsymphony RGQ MDx
Clearance marks a milestone for one of the Company’s major global growth drivers.
Monday, May 05, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
QIAGEN and Exosome Diagnostics Expand Partnership
Partnership aims to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and monitoring patients.
Monday, January 13, 2014
QIAGEN Reports Second Quarter 2013 Results and Announces New Share Repurchase Program
Company is building momentum in Personalized Healthcare with FDA approval of therascreen EGFR companion diagnostic and new pharma co-development projects.
Wednesday, July 31, 2013
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos